Published on 20 September 2025, the document – Expedited Programs for Regenerative Medicine Therapies for Serious Conditions – replaces earlier 2019 guidance and provides updated direction for companies developing cell- and gene-based treatments. It explains how products may qualify for the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, as well as accelerated approval and priority review routes.  

The guidance sets out clearer expectations on manufacturing quality, comparability between batches, and long-term safety monitoring; acknowledging that regenerative products often have lasting or one-time effects that require extended follow-up. It also encourages the use of real-world evidence and digital health tools to support regulatory submissions and post-market surveillance.  

While primarily focused on therapies for serious or life-threatening conditions, the guidance reflects the FDA’s broader commitment to modernising its regulatory framework for regenerative products. This could have implications beyond advanced biopharmaceuticals, as standards for manufacturing, data collection and safety oversight increasingly influence adjacent fields such as aesthetic and functional medicine.  

The FDA is accepting public comments on the draft until 24 November 2025.